Topic summary

Dextromethorphan/bupropion

Dextromethorphan/bupropion

Dextromethorphan/bupropion, sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD) and agitation associated with dementia due to Alzheimer's disease. Its active components are dextromethorphan (DXM) and bupropion. It is taken as a tabletby mouth.

Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.

Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.